Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Forendo Pharma
Turku, Finlandforendo.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Forendo Pharma developed first-in-class oral small molecule therapies targeting tissue-specific hormone regulation. Its lead candidate, FOR‑6219, an HSD17B1 inhibitor for endometriosis, entered Phase II trials. A second preclinical program targeted PCOS. The company also had a strategic collaboration with Novartis on chronic liver disease using its HSD17B platform. In December 2021, Organon acquired the company to expand its women’s health pipeline.
- Therapeutic areas
- GastroenterologyWomen's HealthEndocrinologyMen's Health
- Modalities
- small molecules
- Industry
- Biotech
02
Partnerships
Novartis – strategic collaboration leveraging HSD17B platform in chronic liver diseases
Beyond the preview
Go deeper on Forendo Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Forendo Pharma.